India · Delayed Price · Currency is INR RPG Life Sciences Earnings Call Transcripts
Fiscal Year 2026
-
Q4 FY26 saw 23.6% revenue growth and 48% EBITDA growth, with strong domestic and API recovery. Margin stabilization is expected as the API plant is fully operational, and new product launches and market expansion are set to drive future growth.
-
Domestic formulations grew 17.2% YOY in Q2, outpacing the market, while API business is set to recover in H2 after a fire. EBITDA margin remains strong at 24%, and the company maintains a debt-free, cash-rich position, with continued expansion and digital initiatives.
Fiscal Year 2025
-
Q4 FY25 saw revenue up 12.7% and strong profit growth, with margins expanding across all segments. Cash surplus reached INR 266 crore, and all business lines are set for further growth, supported by modernized plants and a robust product pipeline.
-
Achieved 14.7% growth, double the market rate, with record EBITDA margin of 27.8% and all segments posting double-digit growth. Strategic focus on international expansion, R&D, and M&A, supported by strong cash surplus and plant upgrades.
Fiscal Year 2024
-
INR 32.2 crore will be paid as a one-time expense in Q2 for MIDC transfer charges, while INR 144.9 crore from the assignment of API plant land is expected to be recognized in Q3, supporting future M&A and growth initiatives. Cash surplus will be used for expansion and acquisitions.